Mri Contrast Agent Patents (Class 977/930)
-
Patent number: 8961935Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent coated with carboxylated mannan, particularly a carboxylated mannan coated superparamagnetic MRI contrast agent specifically targeting antigen presenting cells and having excellent in vivo stability, and a method for producing the same. The MRI contrast agent coated with carboxylated mannan of the present invention can provide excellent in vivo stability and biocompatibility owing to its high surface negative charge, and can be introduced specifically into antigen presenting cells owing to mannose of mannan, so as to visualize the antigen presenting cells and the tissue containing the antigen presenting cells in MRI.Type: GrantFiled: April 15, 2011Date of Patent: February 24, 2015Assignee: Intron Biotechnology, Inc.Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Sang Hyeon Kang, Yong Yeon Jeong, In Kyu Park, Chong Su Cho, You Kyoung Kim, Won Jong Kim, Ran Namgung
-
Patent number: 8828357Abstract: Iron oxide nano contrast agents for Magnetic Resonance Imaging which have superior T2 contrast effect, and also can be used as a storage or a carrier for drugs and so on, are disclosed. The iron oxide nano contrast agents can be prepared by the steps of: coating surfaces of hydrophobic FeO nanoparticles with a coating material selected from the group consisting of polyethylene glycol-phospholipid conjugate, dextran, chitosan, dimercaptosuccinic acid and mixtures thereof in an organic solvent to form hydrophilic FeO nanoparticles having hydrophilic surfaces and dispersibility in water; dispersing the hydrophilic FeO nanoparticles in water to oxidize FeO; and exposing the oxidized hydrophilic FeO nanoparticles to an acidic buffer to dissolve and remove interior unoxidized FeO portions, and thereby to form Fe3O4 nanoparticles having an interior space.Type: GrantFiled: July 31, 2013Date of Patent: September 9, 2014Assignee: Korea Basic Science InstituteInventors: Chulhyun Lee, Sung Lan Jeon, Min Kyung Chae, Jee-Hyun Cho, Eun Ju Jang
-
Publication number: 20140227186Abstract: Nanoparticle delivery systems for use in targeting biologically active agents to the central nervous system comprise a composition comprising (a) a nanoparticle comprising: (i) a core comprising a metal and/or a semiconductor; and (ii) a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise a carbohydrate, insulin and/or a glutathione; and (b) the at least one agent to be delivered to the CNS. Methods of treatment and diagnosing CNS disorders utilising the nanoparticle delivery systems and related screening methods are also disclosed.Type: ApplicationFiled: February 7, 2014Publication date: August 14, 2014Inventors: Thomas Rademacher, David K. Male
-
Patent number: 8747839Abstract: At least one embodiment of the invention relates to bone marrow precursor cells or bone marrow cells of a patient, the cells labeled with at least one contrast agent suitable for an imaging method, for use in an imaging method for diagnosing a metastasizing cancer, wherein the local accumulation of the labeled precursor cells or bone marrow cells indicates the presence of a metastasizing tumor growth. At least one embodiment also relates to a method for imaging a metastasizing tumor tissue in a patient, wherein a) bone marrow precursor cells or bone marrow cells are extracted from a patient, b) these precursor cells or bone marrow cells are labeled with at least one contrast agent suitable for an imaging method, c) the precursor cells or bone marrow cells thus labeled are retransplanted or reinjected into the patient, and d) the presence of metastasizing tumor cells is depicted with an imaging method.Type: GrantFiled: December 21, 2010Date of Patent: June 10, 2014Assignees: Siemens Aktiengesellschaft, Siemens Healthcare Diagnostics Products GmbHInventors: Christian Geppert, Arne Hengerer, Sven Meyburg, Sebastian Schmidt, Susanne Schmolke, Ralph Markus Wirtz
-
Publication number: 20140147391Abstract: A bioprobe based on surface-modified single-phase BaGdF5:Yb/Er upconversion nanoparticles (UCNPs) for multi-modal bioimaging of fluorescent, magnetic resonance imaging (MRI) and computed X-ray tomography (CT) is disclosed herein. The modified UCNPs of the present invention are synthesized by a facile one-pot hydrothermal method with simultaneous surface modification of the nanoparticles. The surface-modified UCNPs of the present invention are useful in a variety of biomedical application fields due to their advantages in in vitro and in vivo multi-modal bioimaging such as small particle size up to 15 nm, substantially free of autofluorescence, low cytotoxicity, capable of being excited at near-infrared (NIR) wavelength, ability to deep cell penetration, long-lasting signal and long circulation time in vivo, different X-ray absorption coefficients at different photon energy levels between Ba and Gd, large magnetic moment, etc.Type: ApplicationFiled: November 28, 2012Publication date: May 29, 2014Applicant: THE HONG KONG POLYTECHNIC UNIVERSITYInventors: Jianhua HAO, Songjun ZENG
-
Patent number: 8728529Abstract: Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety.Type: GrantFiled: December 29, 2008Date of Patent: May 20, 2014Assignee: General Electric CompanyInventors: Matthew David Butts, Robert Edgar Colborn, Peter John Bonitatibus, Jr., Amit Mohan Kulkarni, Bruce Allan Hay, Andrew Soliz Torres, Brian Christopher Bales, Michael Ernest Marino
-
Patent number: 8697813Abstract: The present invention relates to a reversible fluorescence photoswitch based on the dye-crosslinked dendritic nanoclusters for high-contrast imaging of living biological systems. The dendritic nanocluster according to the present invention consists of two or more dendrimers crosslinked each other to have a globular shape overall, and thereby enhancing the fluorescence intensity and improving the detection sensitivity of the monomeric dendrimers. In addition, the dendritic nanocluster according to the present invention was found to internalize into a living zebrafish by both skin permeation and microinjection, independently. Further, the dendritic nanocluster according to the present invention showed low toxicity and thus it could be useful for both in vivo and in vitro imaging as well as the ex vivo cell tracking applications.Type: GrantFiled: August 26, 2011Date of Patent: April 15, 2014Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Yoonkyung Kim, Hye-youn Jung, Bong Hyun Chung
-
Publication number: 20140056819Abstract: The present invention provides a trialkoxysilanes having structure I wherein R1 and R2 are independently at each occurrence a C1-C3 alkyl group; R3 is independently at each occurrence a hydrogen or a C1-C3 alkyl group; R4 is a C1-C5 aliphatic radical, a C7-C12 aromatic radical, or a C5-C10 cycloaliphatic group; n is 0, 1, 2 or 3; q is 1, 2 or 3; and X? represents a charge balancing counterion. The trialkoxysilanes are useful for the preparation of nanoparticulate diagnostic imaging agent compositions.Type: ApplicationFiled: August 23, 2012Publication date: February 27, 2014Applicant: GENERAL ELECTRIC COMPANYInventors: Matthew David Butts, Peter John Bonitatibus, JR., Robert Edgar Colborn, Andrew Soliz Torres
-
Publication number: 20130315839Abstract: Iron oxide nano contrast agents for Magnetic Resonance Imaging which have superior T2 contrast effect, and also can be used as a storage or a carrier for drugs and so on, are disclosed. The iron oxide nano contrast agents can be prepared by the steps of: coating surfaces of hydrophobic FeO nanoparticles with a coating material selected from the group consisting of polyethylene glycol-phospholipid conjugate, dextran, chitosan, dimercaptosuccinic acid and mixtures thereof in an organic solvent to form hydrophilic FeO nanoparticles having hydrophilic surfaces and dispersibility in water; dispersing the hydrophilic FeO nanoparticles in water to oxidize FeO; and exposing the oxidized hydrophilic FeO nanoparticles to an acidic buffer to dissolve and remove interior unoxidized FeO portions, and thereby to form Fe3O4 nanoparticles having an interior space.Type: ApplicationFiled: July 31, 2013Publication date: November 28, 2013Applicant: KOREA BASIC SCIENCE INSTITUTEInventors: Chulhyun LEE, Sung Lan JEON, Min Kyung CHAE, Jee-Hyun CHO, Eun Ju JANG
-
Publication number: 20130287703Abstract: The present invention relates to a nanophosphor and a synthesis method thereof, and provides a nanophosphor comprising a first compound of Formula 1, wherein the first compound is fluoride-based one which is co-doped with Ce3+ and Tb3+. NaGd1?p?q?rMrF4:Ce3+p,Tb3+q ??(1) In the Formula 1, descriptions on the p, q, r and M are overlapped with what was described in the detailed description of the present invention, so their concrete description are omitted. The nanophosphor has good light emission intensity and magnetic property as well as up-conversion and/or down-conversion property able to emit visible light after excitation by infrared and/or ultraviolet rays, so can be applied to a contrast agent and a counterfeit prevention code.Type: ApplicationFiled: April 24, 2013Publication date: October 31, 2013Applicant: Korea Institute Of Science And TechnologyInventors: Ho Seong JANG, Kyoungja WOO, Kipil LIM
-
Patent number: 8562944Abstract: A composition comprising PAA nanoparticles containing a post loaded tetrapyrollic photosensitizer and an imaging agent and methods for making and using same.Type: GrantFiled: October 21, 2010Date of Patent: October 22, 2013Assignees: Health Research, Inc., The Research Foundation of State University of NY, Regents of the University of MichiganInventors: Ravindra K. Pandey, Raoul Kopelman, Anurag Gupta, Munawwar Sajjad
-
Patent number: 8557290Abstract: The present invention relates to nanoconjugates. In particular, the present invention provides nanoconjugates for diagnostic (e.g., imaging), research, and clinical (e.g., targeted treatment) applications.Type: GrantFiled: March 13, 2009Date of Patent: October 15, 2013Assignee: Northwestern UniversityInventors: Ai-Guo Wu, Tatjana Paunesku, Gayle E. Woloschak
-
Publication number: 20130230463Abstract: The present application discloses nanoparticles, particularly nanoparticles of superparamagnetic iron oxide, which find utility in iron therapy and diagnostic imaging such as magnetic resonance (MR). The disclosed nanoparticles have been treated with an ?-hydroxyphosphonic acid conjugate containing polyethylene glycol as a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are polyethylene oxide-based polymers and have a molecular weight greater than 5,000 dalton and less than or equal to about 30,000 daltons. Surprisingly, these nanoparticles have a more rapid and complete processing in liver of retained nanoparticles when compared to similar nanoparticles in which the PEG-based hydrophilic moiety has a molecular weight less than 5,000.Type: ApplicationFiled: March 2, 2012Publication date: September 5, 2013Applicant: GENERAL ELECTRIC COMPANYInventors: Bruce Allan HAY, Daniel Eugene MEYER, Brian Christopher BALES, Michael Todd LUTTRELL
-
Publication number: 20130195766Abstract: The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and/or therapy. The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRI) and/or in other diagnostic techniques and/or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies.Type: ApplicationFiled: May 2, 2011Publication date: August 1, 2013Applicants: NANOH, INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON, UNIVERSITE LYON 1 CLAUDE BERNARDInventors: François Lux, Olivier Tillement, Maxime Saint Jean, Pierre Mowat, Pascal Perriat, Stéphane Roux, Anna Mignot
-
Publication number: 20130164222Abstract: Provided are a preparation method of iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles, iron oxide-based nanoparticles prepared by the same, and a T1 contrast agent including the same. More particularly, the disclosure describes a method for preparation of iron oxide nanoparticles having a extremely small and uniform size of 4 nm or less based on thermal decomposition of iron oleate complex, iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles prepared by the same, and a T1 contrast agent including iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles.Type: ApplicationFiled: August 5, 2011Publication date: June 27, 2013Applicant: Hanwha Chemical CorporationInventors: Taeg Hwan Hyeon, Byung Hyo Kim, No Hyun Lee, Eung Gyu Kim, Bong Sik Jeon, Eun Byul Kwon, Ju Young Park, Wan Jae Myeong
-
Publication number: 20130129636Abstract: The present invention provides novel liposomes comprising Gd.DOTA.DSA (gadolinium(III)2-{4,7-bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N?-amido-methyl]-1,4,7,10-tetra-azacyclododec-1-yl}-acetic acid), characterised in that said liposome further comprises a neutral, fully saturated phospholipid component (e.g. DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine]), which are of particular use in the preparation of magnetic resonance contrast agents for enhancing a magnetic resonance image of tumours in a mammal.Type: ApplicationFiled: November 19, 2010Publication date: May 23, 2013Applicants: IMPERIAL INNOVATIONS LIMITED, MEDICAL RESEARCH COUNCILInventors: Nazila Kamaly, Tammy Louise Kalber, Gavin David Kenny, Maya Thanou, Andrew David Miller, Jimmy Bell
-
Publication number: 20130129632Abstract: The disclosure provides quantum dot materials, compositions and methods useful in the treatment of various disorders. In particular, the disclosure provides cadmium-free and lead-free quantum dots.Type: ApplicationFiled: October 3, 2012Publication date: May 23, 2013Inventors: Kam W. Leong, Chai-Hoon Quek
-
Patent number: 8440229Abstract: The disclosure provide hollow nanospheres and methods of making and using the same. The methods and compositions of the disclosure are useful for drug delivery and gene transfer.Type: GrantFiled: August 13, 2008Date of Patent: May 14, 2013Assignee: The Regents of the University of CaliforniaInventors: William C. Trogler, Sadik C. Esener, Davorka Messmer, Johan Ulrik Lind, Kristina K. P. Mitchell, Jian Yang
-
Publication number: 20130115172Abstract: The present invention relates to a nanophosphor and method for synthesizing the same, and provides a nanophosphor containing fluoride-based nanoparticles co-doped with Yb3+ and Er3+ expressed by the following Chemical Formula 1, NaY1?w?z?x?yGdwLzF4:Yb3+x,Er3+y??(1) wherein, the description of the values x, y, w, z, and L is the same as defined above. The nanophosphor may exhibit an excellent luminous intensity despite having a small particle size, and be excited by infrared rays to emit visible light, and have magnetic properties and thus can be used as a contrast agent, a counterfeit prevention code, and the like.Type: ApplicationFiled: November 7, 2012Publication date: May 9, 2013Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventor: Korea Institute of Science and Technology
-
Publication number: 20130108554Abstract: The present invention relates generally to multimodal magnetic resonance imaging (MRI) contrast agents. In particular, the present invention provides a MRI contrast agent configured to manipulate both the longitudinal (T1) and transverse (T2) relaxation times of surrounding water proton spins.Type: ApplicationFiled: December 19, 2012Publication date: May 2, 2013Applicant: Northwestern UniversityInventors: Elise A. Schultz Sikma, Mohammed Aslam, Vinayak P. Dravid, Thomas J. Meade, Bradley D. Ulrich
-
Publication number: 20130064759Abstract: An emulsion includes a substantially continuous liquid medium, and a plurality of droplet structures dispersed within the substantially continuous liquid medium. Each droplet structure of the plurality of droplet structures includes an outer droplet of a first liquid having an outer surface; an inner droplet of a second liquid within the first droplet, the second liquid being immiscible in the first liquid, wherein the inner and outer droplets have a boundary surface region therebetween; an outer layer of block copolymers disposed on the outer surface of the outer droplet; and an inner layer of block copolymers disposed on the boundary surface region between the outer and the inner droplets.Type: ApplicationFiled: September 5, 2012Publication date: March 14, 2013Applicant: The Regents of the University of CaliforniaInventors: Thomas G. Mason, Timothy J. Deming, Jarrod A. Hanson, Connie B. Chang, Sara M. Graves
-
Publication number: 20130052140Abstract: This invention provides a Fe3O4/TiO2 composite nano-particle, its preparation and application in the magnetic resonance imaging (MRI) contrast agent, wherein the preparation of Fe3O4/TiO2 composite nano-particles has the followings steps: trivalent iron compounds and bivalent iron compounds are dissolved into a reducing acid water solution, and then added with tetravalent titanium salt solution to obtain the Fe3O4/TiO2 composite nano-particle sol. The Fe3O4/TiO2 composite nano-particles prepared by the method in the invention have the properties of superparamagnetism and photocatalytic activity and can be applied to MRI contrast agents.Type: ApplicationFiled: October 15, 2010Publication date: February 28, 2013Inventors: Leyong Zeng, Aiguo Wu, Ping Cui
-
Publication number: 20130039858Abstract: Novel fluorescent dye comprising metal oxide nanoparticles are prepared where the nanoparticles are as small as 3 nm or up to 7000 nm in diameter and where the dye is bound within the metal oxide matrix. In some embodiments the invention, novel dyes are covalently attached to the matrix and in other embodiments of the invention a dye is coordinate or ionic bound within the metal oxide matrix. A method for preparing the novel covalently bondable modified fluorescent dyes is presented. A method to prepare silica comprising nanoparticles that are 3 to 8 nm in diameter is presented. In some embodiments, the fluorescent dye comprising metal oxide nanoparticles are further decorated with functionality for use as multimodal in vitro or in vivo imaging agents. In other embodiments of the invention, the fluorescent dye comprising metal oxide nanoparticles provide therapeutic activity and incorporated therapeutic temperature monitoring.Type: ApplicationFiled: February 24, 2011Publication date: February 14, 2013Applicant: University of Florida Research Foundation, Inc.Inventors: Scott Chang Brown, Amit Kumar Singh, Parvesh Sharma, Brij M. Moudgil, Stephen R. Grobmyer
-
Publication number: 20130039848Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as polyethylene glycol) (PEG) The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo The nanoparticle may further be conjugated to a ligand capable of binding to a cellular component associated with the specific cell type, such as a tumor marker A therapeutic agent may be attached to the nanoparticle Radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle to permit the nanoparticle to be detectable by various imaging techniques.Type: ApplicationFiled: July 2, 2010Publication date: February 14, 2013Applicants: CORNELL UNIVERSITY, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Michelle Bradbury, Ulrich Wiesner, Oula Penate Medina, Hoosweng Ow, Andrew Burns, Jason Lewis, Steven Larson
-
Publication number: 20130023714Abstract: In one embodiment the present invention discloses a nanocluster or a nanorose composition comprising two or more closely spaced nanoparticles each comprising one or more metals, metal oxides, inorganic substances, or a combination thereof and one or more stabilizers. The stabilizers are in contact with the two or more closely spaced nanoparticles to form a nanocluster composition in which the inorganic weight percentage is greater than 50% and the average size is below 300 nm, and the nanocluster composition has magnetic properties, optical properties or a combination of both.Type: ApplicationFiled: October 26, 2009Publication date: January 24, 2013Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMSInventors: Keith P. Johnston, Li L. Ma, Marc D. Feldman, Thomas E. Milner, Konstantin V. Sokolov, Jasmine Rowe, Justina Tam, Stanislav Emelianov, Kort Travis, Avinash K. Murthy
-
Publication number: 20120276011Abstract: A new class of micro- and nano-particulate paramagnetic spin probes useful for magnetic resonance imaging techniques, including electron paramagnetic resonance (EPR) and magnetic resonance imaging (MRI). The probes are lithium phthalocyanine derivative compounds. Also provided are suspensions and emulsions comprising lithium phthalocyanine derivative probes. Also provided are noninvasive methods for measuring noninvasive methods of measuring oxygen concentration, oxygen partial pressure, oxygen metabolism, and nitric oxide concentration in a specific tissue, organ, or cell in vivo or in vitro.Type: ApplicationFiled: November 29, 2011Publication date: November 1, 2012Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Periannan Kupussamy, Vijay Kutala, Jay L. Zweier, Pawel Kwiatkowski
-
Publication number: 20120276016Abstract: The invention relates to a polymer comprising a segment of Formula (I): wherein, R is either absent or a linking group, n is an integer greater than 0; and m is an integer from 1 to 6.Type: ApplicationFiled: October 28, 2010Publication date: November 1, 2012Applicant: Agency for Science, Technology and ResearchInventors: Jackie Y. Ying, Subramanian T. Selvan, Nandanan Erathodiyil, Alex Wei Haw Lin
-
Publication number: 20120269736Abstract: This invention relates to a composition comprising a micelle for use in biological applications, the micelle comprising: a substantially water-insoluble conjugated polymer which exhibits luminescence or fluorescence from about 300 nm to about 1500 nm of the electromagnetic spectrum: a biocompatible surfactant and/or lipid: and a MRI active agent.Type: ApplicationFiled: September 28, 2010Publication date: October 25, 2012Applicant: KING'S COLLEGE LONDONInventors: Mark Green, Philip Howes
-
POLYMER COATED FERRITE FINE PARTICLES AND METHOD FOR PREPARING POLYMER COATED FERRITE FINE PARTICLES
Publication number: 20120269737Abstract: [Object] To provide a polymer coated ferrite fine particles being possible to control a particle size uniformly while having high aqueous dispersibility and preferred biomolecule immobilization ability and an easy method for preparing the same. [Means Addressing Object] In an aqueous solvent, iron ion is protected by chelating polyacrylic acid and then alkaline is added. Thereafter, a reaction system is heated under pressurized condition to produce simultaneous precipitation of the ferrite fine particles and coating thereof. As the result, the polymer coated ferrite fine particles having uniform particle size may be prepared in one step with excellent reproducibility. The polymer coated ferrite fine particles of the present invention has high water dispersibility and has preferred biomolecule immobilization performance by carboxyl groups coming from the polyacrylic acid.Type: ApplicationFiled: October 28, 2010Publication date: October 25, 2012Applicant: TOKYO INSTITUTE OF TECHNOLOGYInventors: Hiroshi Handa, Mamoru Hatakeyama, Satoshi Sakamoto, Hiroshi Kishi -
Publication number: 20120230919Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent coated with carboxylated mannan, particularly a carboxylated mannan coated superparamagnetic MRI contrast agent specifically targeting antigen presenting cells and having excellent in vivo stability, and a method for producing the same. The MRI contrast agent coated with carboxylated mannan of the present invention can provide excellent in vivo stability and biocompatibility owing to its high surface negative charge, and can be introduced specifically into antigen presenting cells owing to mannose of mannan, so as to visualize the antigen presenting cells and the tissue containing the antigen presenting cells in MRI.Type: ApplicationFiled: April 15, 2011Publication date: September 13, 2012Applicant: INTRON BIOTECHNOLOGY, INC.Inventors: Seong Jun YOON, Soo Youn JUN, An Sung KWON, Sang Hyeon KANG, Yong Yeon JEONG, In Kyu PARK, Chong Su CHO, You Kyoung KIM, Won Jong KIM, Ran NAMGUNG
-
Publication number: 20120220734Abstract: The present invention relates to a reversible fluorescence photoswitch based on the dye-crosslinked dendritic nanoclusters for high-contrast imaging of living biological systems. The dendritic nanocluster according to the present invention consists of two or more dendrimers crosslinked each other to have a globular shape overall, and thereby enhancing the fluorescence intensity and improving the detection sensitivity of the monomeric dendrimers. In addition, the dendritic nanocluster according to the present invention was found to internalize into a living zebrafish by both skin permeation and microinjection, independently. Further, the dendritic nanocluster according to the present invention showed low toxicity and thus it could be useful for both in vivo and in vitro imaging as well as the ex vivo cell tracking applications.Type: ApplicationFiled: August 26, 2011Publication date: August 30, 2012Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHInventors: Yoonkyung Kim, Hye-Youn Jung, Bong Hyun Chung
-
Publication number: 20120219496Abstract: The invention relates to nanocluster compositions and uses thereof. Specifically, the invention relates to gadolinium-linked nanocluster compositions and their use in diagnosis and prognosis of diseases. The nanocluster compositions of the invention are effective in enhancing the payload of a gadolinium and thereby increasing the longitudinal relaxivity of each particle in the cluster.Type: ApplicationFiled: August 30, 2010Publication date: August 30, 2012Inventors: Andrew Tsourkas, Zhiliang Cheng
-
Publication number: 20120201760Abstract: A T1 blood pool contrast agent comprising very small iron oxide nanoparticles are coated with poly(ethylene glycol) (PEG) based ligands. Core size and length of the PEG chain were optimized according to stability, relaxometric properties, cytotoxicity and unspecified cell uptake.Type: ApplicationFiled: August 9, 2010Publication date: August 9, 2012Inventors: Ulrich Ingmar Tromsdorf, Oliver Thomas Bruns, Horst Weller
-
Publication number: 20120195835Abstract: A bio-imaging nanoparticle is composed of a core nanoparticle, a bonding layer having organic ligands, surfactants and polyoxyalkylene derivatives of fatty acid ester, and veiling the core nanoparticle, and functional molecules, wherein the organic ligands are bound to a surface of the core nanoparticle, the surfactants are bound to a portion of the surface of the core nanoparticle to which the organic ligands are not bound, the polyoxyalkylene derivatives of the fatty acid ester are introduced in an empty space between the organic ligands and the surfactants of the bonding layer, and the functional molecule is bound to a second terminal end opposite to a first terminal end of both terminal ends of the organic ligand, the first terminal end of the organic ligand being bound to a shell of the core nanoparticle.Type: ApplicationFiled: January 27, 2012Publication date: August 2, 2012Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Kyoungja WOO, Myung-Ik YOO
-
Publication number: 20120197114Abstract: Nanocarriers and methods of preparation and use of nanocarriers are presented. In some embodiments, a nanocarrier composition comprises an organic liquid comprising a plurality of nanoparticles dispersed therein; and a coating material disposed around the exterior surface of the organic liquid. Biological tissue may be imaged or treated by coming into contact with a nanocarrier composition, and, at least in some embodiments, irradiated.Type: ApplicationFiled: March 21, 2012Publication date: August 2, 2012Inventors: Stanislav Emelianov, Katheryne Wilson, Kimberly Homan
-
Publication number: 20120141380Abstract: The invention provides nanoparticles consisting of a polymer which is a metal chelating agent coated with a magnetic metal oxide, wherein at least one active agent is covalently bound to the polymer, said nanoparticles may optionally further comprise at least one active agent physically or covalently bound to the outer surface of the magnetic metal oxide. Pharmaceutical compositions comprising these nanoparticles may be used, inter alia, for detection and treatment of tumors and inflammations.Type: ApplicationFiled: December 22, 2011Publication date: June 7, 2012Applicants: HENRY FORD HOSPITAL, BAR ILAN UNIVERSITYInventors: Shlomo Margel, Benny Perlstein, Chaya Brodie, Tom Mikkelsen
-
Publication number: 20120134932Abstract: Nanoparticles for use as magnetic resonance imaging contrast agents are described. The nanoparticles are made up of a polymeric support and a manganese-oxo or manganses-iron-oxo cluster having magnetic properties suitable of a contrast agent. The manganese-oxo clusters may be Mn-12 clusters, which have known characteristics of a single molecule magnet. The polymer support may form a core particle which is coated by the clusters, or the clusters may be dispersed within the polymeric agent.Type: ApplicationFiled: October 21, 2009Publication date: May 31, 2012Applicant: Georgetown UniversityInventors: Sarah Stoll, Julie Mertzman, Edward Van Keuren, Christopher Albanese, Stanley Fricke
-
Publication number: 20120128583Abstract: The present invention relates to DTPA derivatives capable of forming complexes by combining with metals and the like, metal complexes formed by combining with the DTPA derivatives, MR and CT contrast agents including gold (Au) nano-particles of which surfaces are coated with the metal complexes, and a method for manufacturing the same. The MR and CT contrast agents according to the present invention have a high magnetic relaxation rate, thereby providing an excellent contrast enforcement effect and a long image acquisition time. Furthermore, the MR and CT contrast agents are not toxic to the human body, and are image contrast agents of dual molecules capable of being applied to both MR and CT.Type: ApplicationFiled: December 13, 2009Publication date: May 24, 2012Applicant: Kyungpook National University Industry Academic Cooperation FoundationInventors: Tae Jung Kim, Yong Min Jang, Ji Ae Park
-
Publication number: 20120128589Abstract: Described is the use of perfluoro-t-butyl cyclohexane in a contrast agent for molecular imaging, notably F MRI. Particularly, the perfluoro-t-butyl cyclohexane is present in the form of an aqueous emulsion of nanoparticles comprising the perfluoro compound as a core, and an emulsifying agent, such as a phospholipid, as a shell. The shell can be functionalized with other moieties that play a role in imaging, notably ligands for targeted binding and/or contrast agents or labels with a view to other imaging modalities. The latter particularly refers to 1H MRI contrast agents as well as radiolabels for SPECT.Type: ApplicationFiled: July 21, 2010Publication date: May 24, 2012Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Muhammed Yildirim, Holger Gruell, Rudolf Mathias Johannes Nicolaas Lamerichs
-
Publication number: 20120121507Abstract: Peptides are disclosed that are useful for molecular imaging or diagnosis of a disease state, such as cancer, in which clusterin is upregulated.Type: ApplicationFiled: April 15, 2010Publication date: May 17, 2012Inventors: Rana Filfil, Dmitri Tolkatchev, Feng Ni, Maureen D. O'Connor-McCourt, Anne E. G. Lenferink
-
Publication number: 20120121517Abstract: The present invention relates to a poly(organophosphazene)-superparamagnetic nanoparticle complex including a biodegradable and thermosensitive poly(organophosphazene) and a iron oxide (Fe3O4, Magnetite)-series ferrite superparamagnetic nanoparticle, a preparation method, and uses of carrying a physiologically-active material, a bio-material and a biomaterial for cancer hyperthermia. The iron oxide is used as a MRI contrast agent for T-2 and T2* weighted image, and the poly(organophosphazene) shows a sol-to-gel behavior depending upon the temperature change. The complex is a bound-type where the superparamagnetic ferrite nanoparticle is bonded to phosphazene-based polymer via hydrophobic binding, and a mixed-type where the superparamagnetic ferrite nanoparticle is physically mixed with the phosphazene-based polymer.Type: ApplicationFiled: June 30, 2011Publication date: May 17, 2012Inventors: Soo-Chang SONG, Jang Il KIM
-
Publication number: 20120121518Abstract: Multifunctional nanoparticles for imaging and therapeutic drug delivery made from amphiphilic block copolymers having a hydrophobic block and one or more hydrophilic blocks, and at least one internal and one terminal chelating agent units having a paramagnetic metal ion associated therewith.Type: ApplicationFiled: November 16, 2011Publication date: May 17, 2012Inventors: Zhihua Lu, Thomas Hirt
-
Publication number: 20120114564Abstract: The present invention relates to the use of and method for using MnO nanoparticles as MRI T1 contrasting agents which reduces T1 of tissue. More specifically, the present invention is directed to MRI T1 contrasting agent comprising MnO nanoparticle coated with a biocompatible material bound to a biologically active material such as a targeting agent, for example tumor marker etc., and methods for diagnosis and treatment of tumor etc. using said MRI T1 contrasting agent, thereby obtaining more detailed images than the conventional MRI T1-weighted images. The MRI T1 contrasting agent of the present invention allows a high resolution anatomic imaging by emphasizing T1 contrast images between tissues based on the difference of accumulation of the contrasting agent in tissues. Also, the MRI T1 contrasting agent of the present invention enables to visualize cellular distribution due to its high intracellular uptake.Type: ApplicationFiled: January 30, 2008Publication date: May 10, 2012Applicant: SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATIONInventors: Taeghwan Hyeon, Kwangjin An, Hyon Bin Na, Junghee Lee
-
Publication number: 20120107246Abstract: Methotrexate-modified nanoparticles that target tumors, compositions that include the nanoparticles, methods of imaging tissues using the nanoparticles, and methods for treating tissues using the nanoparticles.Type: ApplicationFiled: June 18, 2010Publication date: May 3, 2012Applicant: WASHINGTON, UNIVERSITY OFInventors: Miqin Zhang, Shian-Jy Wang, Nathan Kohler, Yuh-Jiuan Lin, Conroy Sun
-
Publication number: 20120107229Abstract: The present inventions relate to compositions and methods for imaging and treating atherosclerotic diseases, pathogen infections, and tumors by administering actively targeting magnetic nanoparticles. In particular, the present inventions provide new types of targeting ligands attached to magnetic nanoparticles for magnetic resonance imaging. The use of these targeted magnetic nanoparticles is contemplated as a means to treat atherosclerotic diseases, including but not limited to inhibiting and removing atherosclerotic plaques. Further, actively targeting magnetic nanoparticles are contemplated for use with multiple labels for use in nuclear medicine imaging, computed tomography (CT) techniques and other types of imaging for medical and research applications.Type: ApplicationFiled: April 14, 2010Publication date: May 3, 2012Inventors: Xuefei Huang, David Zhu, George Abela
-
Publication number: 20120082616Abstract: The present invention provides targeted delivery compositions and their methods of use in treating and diagnosing a disease state in a subject.Type: ApplicationFiled: September 23, 2011Publication date: April 5, 2012Applicant: Mallinckrodt LLCInventors: Bobby N. Trawick, Todd A. Osiek, James R. Wheatley, JR.
-
Publication number: 20120076737Abstract: Nanoparticles are used as a contrast agent for magnetic resonance imaging and computed tomography. Each of the nanoparticles includes a metal alloy core and a plurality of hydrophilic molecules covalently bound to the surface of the metal alloy core. Also disclosed is a method for using the contrast agent.Type: ApplicationFiled: March 23, 2011Publication date: March 29, 2012Applicants: National Cheng Kung University, National Taiwan Normal UniversityInventors: Chia-Chun Chen, Dar-Bin Shieh, Shang-Wei Chou, Ping-Ching Wu
-
Publication number: 20120070383Abstract: The present invention features compositions in which nano-carriers are synthesized with polymers that respond to lower pH and/or ROS by being degraded. The compositions may be utilized to selectively deliver payloads within patients by responding to lower pH and/or ROS at localities within the patient. The present invention also features methods of synthesizing nano-carriers that are degraded by lower pH and/or ROS.Type: ApplicationFiled: September 16, 2011Publication date: March 22, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Adah Almutairi, Jagadis Sankaranarayanan, Enas Mahmoud, Eric Schopf
-
Publication number: 20120058053Abstract: A contrast agent characterized in that each of carbon nanohorns forming a carbon nanohorn aggregate has an opening at the side wall or tip, wherein a metal M (at least one metal selected from among paramagnetic metals, ferromagnetic metals, and superparamagnetic metals) or a compound of the metal M is incorporated in or dispersed on each of the carbon nanohorns. A contrast agent characterized in that it contains a Gd oxide. There is provided a contrast agent, which can be mass-produced easily, and satisfies the requirement of low toxicity and enables microscopic diagnoses when used for MRI. A contrast agent characterized in that is contains a carbon nanohorn aggregate.Type: ApplicationFiled: November 14, 2011Publication date: March 8, 2012Inventors: Sumio Iijima, Jin Miyawaki, Masako Yudasaka, Eiichi Nakamura, Hiroyuki Isobe, Hideki Yorimitsu, Hideto Imai
-
Publication number: 20120052006Abstract: The present disclosure is directed generally to gold/lanthanide nanoparticle conjugates, such as gold/gadolinium nanoparticle conjugates, nanoparticle conjugates including polymers, nanoparticle conjugates conjugated to targeting agents and therapeutic agents, and their use in targeting, treating, and/or imaging disease states in a patient.Type: ApplicationFiled: February 17, 2010Publication date: March 1, 2012Applicant: COLORADO SCHOOL OF MINESInventors: Stephen G. Boyes, Misty D. Rowe